Seeking Alpha

diwolf

diwolf
Send Message
View diwolf's Comments BY TICKER:
  • Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
    September sales exploded by ~33% M/M. Sales for DM/PM already are 15, which is great. It took NS sales over one year to get that high.
    Sep 7 08:10 AM | Likes Like |Link to Comment
  • Questcor Pharmaceuticals Breaking $40 And Looking Poised To Begin A New Rally [View article]
    This year, QCOR always rallied when market was falling and fell when market was moving upwards. In my opinion, the shorts have great difficulties to cover at all. There is propably only enough volume when the general market is weak and even then, they drive the price of the stock upwards. The stock has always been rising for years now. Therefore the shorts are under water. Launching a negative report and news may help short term, but long term one has to realise the loss.
    I do think BAC has some great insight into the companies ongoing sales. They would never put QCOR on No1 list if they expect next month/this year bad sales/news.
    Aug 22 09:23 AM | 1 Like Like |Link to Comment
  • Questcor Pharmaceuticals And Citron Research: Who Is Correct? [View article]
    QCOR did react to streetsweeper in January:
    http://bit.ly/woCXQj

    The timing of the short seller attack was excellent. A day before everyone who wanted to buy already bought due to great news. No new buyers and huge profits in a short time make a stock vulnerable to profit taking. Additionally QCOR cannot respond due to the quiet period before earnings release.

    QCOR estimated it sold 400 to 410 paid prescriptions for the leading indication, multiple sclerosis, up at least 50% from June 2011. Anti-nephrotic syndrome prescriptions, which Questcor started actively marketing last year, jumped more than fivefold to 115-120.

    btw. Citronresearch is in fact only one person writing a blog and he is a noted short seller in qcor.
    Jul 13 05:20 AM | 2 Likes Like |Link to Comment
  • Questcor: Why Analysts Are Improving Its Ratings Now [View article]
    Come on. No risk, no return.
    The stock is not falling due to citronresearch. Paper profits are being realised before earnings realease and prior a possible general market crash in autumn, like every summer.
    I think QCOR is propably a buy in autumn again. And when the drug can be really sold for rheumatology, too, this stock is above 100 at least.
    Jul 11 03:47 PM | 1 Like Like |Link to Comment
More on QCOR by diwolf
COMMENTS STATS
7 Comments
5 Likes